Marijuana's Potential Makes This Biotech Stock One of My Favorites

Marijuana has a long history of use in the treatment of illness, and the stigma associated with the drug is waning as more states embrace legalization of medical marijuana and many barriers to access disappear.

Continued momentum in the mainstreaming of medical marijuana could be good news for Insys Therapeutics (NASDAQ: INSY  ) , a biotech company that is awaiting Food and Drug Administration approval of a new formulation of a long-standing marijuana treatment for chemotherapy-induced nausea or anorexia caused by HIV.

Marijuana innovation
The marijuana chemical cannabinoid THC has been available for use by cancer and HIV patients for over 20 years as the FDA-approved drug marinol. Even though the drug has been available since the 1980s, and despite the fact that the market is now dominated by low-price generic formulations, U.S. spending on the marinol still totals...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.fool.com/investing/general/2015/06/13/marijuanas-potential-makes-this-biotech-stock-one.aspx